Shionogi Inc. is the U.S. subsidiary of a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. We’re dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs.
An Opportunity Pipeline
Our world-class research and cutting-edge medical technologies advance innovative therapies and support our focus on delivering revolutionary new products to patients.
Our Research
A Culture of Collaboration
We believe that partnering accelerates our goal of delivering life-saving new therapies to underserved patients. We seek to tailor commercial collaborations to maximize the potential of innovative new therapies.
Partnering Opportunities
Latest News
-
Mar. 6, 2019
FDA Accepts XOFLUZA™ (Baloxavir Marboxil) Supplemental New Drug Application for the Treatment of Influenza in Individuals at High Risk for Influenza-Related Complications
-
Nov. 7, 2018
Shionogi to Present Clinical Data on Mulpleta® (lusutrombopag) at the Liver Meeting® 2018 of the American Association for the Study of Liver Diseases (AASLD)
-
Oct. 25, 2018
Pivotal Trial Results for Shionogi’s Cefiderocol Published in the Lancet Infectious Diseases
Work With Us
Collaboration is central to who we are and how we work. We combine the spirit and nimbleness of an entrepreneurial culture with the resources of a global company.
Career Opportunities